Abzena Completes Relocation

ABZENA COMPLETES RELOCATION TO BABRAHAM RESEARCH CAMPUS, CAMBRIDGE, UK

4 August 2014

Cambridge, UK - Abzena plc (AIM: ABZA) ("Abzena", the "Group" or the "Company"), a revenue-generating life sciences company providing services and technologies that enable the development of better biopharmaceutical products, is pleased to announce that it has completed the relocation of its corporate headquarters and PolyTherics Limited, its wholly owned subsidiary, from London to the Babraham Research Campus near Cambridge, UK.

The move consolidates the Group's main operations at the heart of one of the world's leading clusters for biopharmaceutical innovation. The new headquarters will be home to over 75 scientists from PolyTherics and Antitope, Abzena's other wholly owned subsidiary, creating one of the largest R&D teams in the UK focused on providing high-value services and complementary technologies to identify and create better therapeutic proteins and antibodies.

John Burt, CEO of Abzena, said: "Our relocation to Cambridge's Babraham Research Campus, at the heart of the UK biopharmaceutical industry, marks the next step in the evolution of Abzena following our successful admission to AIM in July this year. Uniting the majority of our employees at one location will strengthen our ability to serve our customers and drive innovation, and positions the Company for longer-term sustainable growth."

###

About Abzena

Abzena provides proprietary technologies and value-added services to enable the development of better biopharmaceuticals.

Abzena comprises two wholly owned subsidiary businesses - PolyTherics and Antitope - which have established a broad suite of complementary technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits.

Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture

PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals.

The Group has built a global customer base over the past decade, including the top 10 pharma, large and small biotech, and academic groups.

Abzena is listed on the AIM segment of the London Stock Exchange under the symbol ABZA.

www.abzena.com 

For more information, please contact:

John Burt (Chief Executive Officer)

Julian Smith (Chief Financial Officer)

Abzena plc

Tel: +44 (0)1223 903498

Email: [email protected] or [email protected]

Christopher Golden and Bobbie Hilliam

Cenkos Securities (Nominated Adviser and Broker)

Tel: +44 (0)20 7397 8900

Mark Swallow, Sita Shah or Chris Gardner

Citigate Dewe Rogerson (Corporate and Financial PR)

Tel: +44 (0)20 7638 9571

Email: [email protected]